search icon
  • Print
  • ShareThis
  • Text Size
  • Federal Funding for Infectious Diseases Programs


    Today’s investment in ID research; public health and prevention; and development of new drugs, vaccines and diagnostics will pay significant dividends in the future. Such investments can prevent needless deaths, dramatically reduce health care costs, and improve the quality of life for millions of Americans and others around the world.  IDSA supports appropriate funding for domestic and international programs including those at the:

    • National Institute for Allergies and Infectious Diseases 
    • Centers for Disease Control and Prevention  
    • Food and Drug Administration 
    • Health Resources Services Administration 
    • U.S. Agency for International Development 
    • National Institute of Health’s Fogarty International Center 


    IDSA’s funding priorities include antimicrobial resistance; immunizations; drug, vaccine and diagnostics development; and HIV/AIDS and tuberculosis prevention and treatment.


    See also:

    HIVMA Federal Funding

    IDSA's Efforts in Advocating for Appropriate Federal Funding for Infectious Diseases Programs


    Need for Antibiotic Resistance Funding Featured in Testimony on FY 2016 (PDF)

    IDSA provided testimony on 2016 funding for infectious diseases priorities to the House subcommittee that has oversight of health spending. The need for funding to implement the National Action Plan for Combating Antibiotic-Resistant Bacteria was featured in the statement.

    IDSA Engages the Senate on 2016 Infectious Diseases Funding Needs (PDF)

    IDSA provided testimony to the Senate panel that oversees federal spending on health programs. The statement encouraged the subcommittee to invest in areas such as antibiotic resistance, rapid diagnostics, immunizations, global health, and neglected tropical diseases.

    IDSA Provides Testimony for Senate Hearing on Ebola Funding (PDF)

    IDSA provided testimony to the Senate Appropriations Committee in support of President Obama's request for emergency funds to deal with the Ebola outbreak.  The Committee solicited stakeholder input ahead of a hearing to discuss the President's request.

    IDSA Provides Testimony on Innovation to the Senate (PDF)

    In preparation for a Senate hearing on the federal role in promoting innovation, IDSA provided testimony on the health and economic gains possible from new public health strategies, vaccines, antibiotics, and rapid diagnostics.

    IDSA Joins Health Groups in Expressing Support for Proposed NIH Innovation Fund (PDF)

    IDSA joined 186 other groups in expressing support for a $10 billion National Institutes of Health Innovation Fund, as included in the House Energy & Commerce Committee's 21st Century Cures bill.  The fund would provide extra support for key areas, including infectious diseases.

    IDSA Helps Promote Funding for CDC Antibiotic Resistance Programs (PDF)

    IDSA joined 53 other health groups in highlighting the need for increased funding for Centers for Disease Control and Prevention programs that address antibiotic resistance. The programs are all critical components of the National Strategy for Combating Antibiotic-Resistant Bacteria.

    IDSA Engages Senate Finance Committee on Incentives to Spur R&D for New Antibiotics and Diagnostics (PDF)

    IDSA wrote to the co-chairs of the Senate Finance Committee's new working group on business tax policy to urge consideration of incentives, such as permanent tax credits, to spur research and development for new antibiotics and rapid infectious diseases diagnostics.

    IDSA Joins 75 Organizations in Promoting Investments in CDC (PDF)

    IDSA joined with other members of the CDC Coalition to urge Congress to provide $7.8 billion in FY 2016 for the Centers for Disease Control and Prevention.  The recommended funding level would support efforts to address antibiotic resistance and promote global health along with a host of other ID priorities.

    Groups Seek Support for Global TB Activities in Anticipation of FY2014 Funding Bill Release (PDF)

    IDSA joined other stakeholders in a letter to Congress seeking $236 million for USAID's TB programs in FY2014.  The letter discusses the impact of TB around the globe and makes special note of the emergence of multidrug-resistant and extensively drug-resistant TB.  USAID is a central partner in efforts to control TB in the world's 30 most highly burdened countries.

    Community Letter Advocating Robust Global Health Efforts (PDF)

    IDSA joined 53 other organizations to urge lawmakers to maintain its funding commitments to improving health in developing countries, without cutting other broader humanitarian efforts and development or imposing any new policy restrictions.

    TB Coalition Letter for Global and Domestic TB Funding (PDF)

    IDSA joined 16 other organizations to urge lawmakers to strengthen U.S. leadership in the fight against TB as envisioned in the Lantos-Hyde Act and Comprehensive TB Elimination Act by investing in global and domestic TB programs at USAID and CDC.


Average 0 out of 5

| HIVMA | Contact Us

© Copyright IDSA 2015 Infectious Diseases Society of America

Full Site Mobile Site